Evidence map›Paper›PMID 30301696›Full record

ArticleEuropean urology2019

A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.

Claire H Pernar, Ericka M Ebot, Andreas Pettersson, Rebecca E Graff, Francesca Giunchi, Thomas U Ahearn, Amparo G Gonzalez-Feliciano, Sarah C Markt, Kathryn M Wilson, Konrad H Stopsack and 8 more

Open access · greenAbstract read
In one paragraph

Article in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Testing forAsian journal of urology · 2021
    Article
  19. Review
  20. Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Claire H PernarDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: cpernar@mail.harvard.edu.
Ericka M EbotDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Andreas PetterssonDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Rebecca E GraffDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Francesca GiunchiPathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy.
Thomas U AhearnDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Amparo G Gonzalez-FelicianoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Sarah C MarktDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Kathryn M WilsonDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Konrad H StopsackDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizaveta GazeevaDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Rosina T LisCenter for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Giovanni ParmigianiDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Eric B RimmDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Stephen P FinnDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Histopathology, Trinity College, Dublin, Ireland.
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Michelangelo FiorentinoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Pathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Harvard University · USBrigham and Women's Hospital · USCase Western Reserve University · USDana-Farber Cancer Institute · USKarolinska Institutet · SEMemorial Sloan Kettering Cancer Center · USTrinity College Dublin · IEUniversity of California, San Francisco · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2M
The HSPH Education and Research Center of Occupational Safety and HealthT42OH008416 · OH · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 2005 to 2025
$30.5M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Training Program in Environmental EpidemiologyT32ES007069 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LADEN, FRANCINE · 1985 to 2024
$13.9M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Sex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer ProgressionR01CA136578 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MUCCI, LORELEI · 2009 to 2013
$1.7M
NCI NIH HHS P30 CA006516NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA090381NCI NIH HHS R01 CA136578NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA167552NIEHS NIH HHS T32 ES007069NIOSH CDC HHS T42 OH008416
6 · The paper itself

Abstract

backgroundGrowing evidence shows that clinical and molecular subtypes of prostate cancer (PCa) have specific risk factors. Observational studies suggest that physical activity may lower the risk of aggressive PCa. To our knowledge, the association between physical activity and PCa defined by TMPRSS2:ERG has not been evaluated.

objectiveTo prospectively examine the association between physical activity and risk of PCa defined by clinical features and TMPRSS2:ERG. DESIGN, SETTING, AND

participantsWe studied 49160 men aged 40-75 yr in the Health Professionals Follow-up Study from 1986 to 2012. Data was collected at baseline and every 2 yr with >90% follow-up. Total and vigorous physical activity were measured in metabolic equivalent of task (MET)-h/wk. OUTCOME MEASURES AND STATISTICAL ANALYSIS: Advanced PCa was defined as stage T3b, T4, N1, or M1 at diagnosis and lethal PCa as distant metastases or death due to disease over follow-up. Presence of TMPRSS2:ERG was estimated by immunohistochemistry of ERG protein expression. Cox proportional hazards models were used to obtain multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of subtype-specific PCa. RESULTS AND LIMITATIONS: During 26 yr of follow-up, 6411 developed PCa overall and 888 developed lethal disease. There were no significant associations between total physical activity and risk of PCa in the overall cohort. In multivariable-adjusted models, men in the highest quintile of vigorous activity had a significant 30% lower risk of advanced PCa (HR: 0.70, 95% CI: 0.53-0.92) and 25% lower risk of lethal PCa (HR: 0.75, 95% CI: 0.59-0.94) than men in the lowest quintile of vigorous activity. The association was independent of screening history. Vigorous activity was not associated with total PCa in the overall cohort but was inversely associated among highly screened men (top vs bottom quintile, HR: 0.83, 95% CI: 0.70-0.97). Of all cases, 945 were assayed for ERG (48% ERG-positive). Men with higher vigorous activity had a lower risk of ERG-positive PCa (top vs bottom quintile, HR: 0.71, 95% CI: 0.52-0.97). There was no significant association with the risk of ERG-negative disease (p heterogeneity=0.09).

conclusionsOur study confirms that vigorous physical activity is associated with lower risk of advanced and lethal PCa and provides novel evidence for a lower risk of TMPRSS2:ERG-positive disease. PATIENT SUMMARY: The identification of modifiable lifestyle factors for prevention of clinically important prostate cancer (PCa) is needed. In this report, we compared risk of PCa in men with different levels of physical activity. Men with higher vigorous activity had a lower risk of developing advanced and lethal PCa and PCa with the common TMPRSS2:ERG gene fusion.

Indexed as

Prostatic NeoplasmsBiomarkers, TumorEffect Modifier, EpidemiologicExerciseFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedNeoplasm StagingOncogene Proteins, FusionProportional Hazards ModelsRisk FactorsSerine EndopeptidasesTranscriptional Regulator ERGBiomarkers, TumorERG protein, humanOncogene Proteins, FusionSerine EndopeptidasesTMPRSS2 protein, humanTranscriptional Regulator ERGExerciseMolecular biomarkersPhysical activityPreventionProstate cancer

Identifiers

PMID30301696
PMCPMC6451672
OpenAlexW2895283056

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.